Role of fluconazole in the management of AIDS-related cryptococcosis, according to daily dosing

Chemotherapy

Volumn 44, Issue 3, 1998, Pages 206-214

  Manfredi, Roberto ^a   Chiodo, Francesco ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

AIDS; Cryptococcosis; Fluconazole, dosing; Prophylaxis

Indexed keywords

FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0031924092     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007116     Document Type: Article

References (46)

1. Powderly W: Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17:837-842.
2. Nelson MR, Fisher M, Cartledge J, Rogers T, Gazzard BG: The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994;8:651-654.
3. Goa KL, Barradell LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658-690.
4. Dismukes WE: Management of cryptococcosis. Clin Infect Dis 1993;17(suppl2):S507-S512.
5. Leenders AC, Van der Ende ME, Van der Ree TC, De Marie S: Cryptococcal meningitis in HIV-infected patients. AIDS 1994;8:1741-1743.
6. Hay RJ: Cryptococcosis, AIDS, and clinical trials. Lancet 1995;345: 530-531.
7. Nightingale SD: Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. Arch Intern Med 1995;155:538-540.
8. Fisher M, Price DA, Klein J, Weston R, Coker RJ: Cryptococcal disease in HIV infection: Treatment and maintenance. AIDS 1995;9: 300-301.
9. Shaunak S, Cohen J: Clinical management of fungal infections in patients with AIDS. J Antimicrob Chemother 1991;28(suppl A):67-82.
10. Powderly WG: Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992;14 (suppl 1):S54-S59.
11. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal agents. N Engl J Med 1994;330:263-272.
12. Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR: Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: Experience with 22 patients. Am J Med 1988;85:477-480.
13. Larsen RA, Leal MA, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990; 113:183-187.
14. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sherkey P, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-89.
15. Dismukes WE: Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-628.
16. Zuger A, Schuster M, Simberkoff MS, Rahal JJ, Holzman RS: Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;109:592-593.
17. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JM: Cryptococcal disease in patients with the acquired immunodeficiency syndrome: Diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-240.
18. Francis P, Walsh TJ: Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15: 1003-1018.
19. White M, Cirrincione C, Blevins A, Armstrong D: Cryptococcal meningitis: Outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-963.
20. Stamm AM, Diasio RB, Dismukes WE: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-242.
21. Chuck SL, Sande MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321: 794-799.
22. Powderly WG: Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(suppl 2): S119-S123.
23. De Lalla F, Pellizzer G, Vaglia A, Manfrin V, Franzetti M, Fabris P, Stecca C: Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: Reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-266.
24. Schürmann D, De Matos Marques B, Grünewald T, Pohle HD, Hahn H, Ruf B: Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infect Dis 1991; 164:620-622.
25. Coker RJ, Viviani M, Gazzard BG, DuPont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JRW: Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-835.
26. Poon M, Cronin DC, Wormser GP, Bottone EJ: In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1988;112:161-162.
27. Casadevall A, Spitzer ED, Webb D, Rinaldi MG: Susceptibilities of Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole: Antimicrob Agents Chemother 1993;37:1383-1386.
28. Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG: In vitro evaluation of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995;39:1691-1695.
29. Peetermans W, Bobbaers H, Verhaegen J, Vandepitte J: Fluconazole-resistant Cryptococcus neoformans var. gattii in an AIDS patient. Acta Clin Belg 1993;48:405-409.
30. Arndt CAS, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG: Fluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-180.
31. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA: High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis 1994;170:238-242.
32. Sitbon O, Fourme T, Bourée P, Du Pasquier L, Salmeron S: Successful treatment of disseminated cryptococcosis with high-dose oral fluconazole. AIDS 1993;7:1685-1687.
33. Sugar AM, Saunders C: Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:481-489.
34. Bozzette SA, Larsen RA, Chiu J, Leal MAE, Jacobsen J, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J, Leedom JM, Richman D, and the California Collaborative Treatment Group: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in acquired immunodeficiency syndrome. N Engl J Med 1991;324:580-584.
35. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE, and the NIAID AIDS Clinical Trials Group, and the NIAID Mycoses Study Group: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:793-798.
36. Meyohas MC, Meynard JL, Bollens D: Treatment of non-meningeal cryptococcosis in patients with AIDS. J Infect 1996;33:7-10.
37. Berry A, Rinaldi M, Graybill J: Use ot high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36:690-692.
38. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19: 741-745.
39. De Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JKM, Van Boxtel CJ, Van Ketel RJ, Stam J: Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-190.
40. Pinner RW, Hajjeh RA, Powderly WG: Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(suppl 1): S103-S107.
41. Menichetti F, Fiorio M, Tosti A, Gatti G, Pasticci MB, Miletich F, Marroni M, Bassetti D, Pauluzzi S: High-dose fuconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22: 838-840.
42. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L: Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: Retrospective analysis of 83 cases. Clin Infect Dis 1996;22(suppl 2): S154-S160.
43. Yew WW, Wong PC, Wong CF, Lee J, Chau CH: Oral fluconazole in the treatment of pulmonary cryptococcosis in non-AIDS patients. Drugs Exp Clin Res 1996;22:25-28.
44. Rozenbaum R, Gonçalves AJR: Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994;18:369-380.
45. Van den Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21.
46. Manfredi R, Mastroianni A, Coronado OV, Chiodo F: Fluconazole as prophylaxis against fungal infections in patients with advanced HIV infection. Arch Intern Med 1997; 157:64-69.